XILIO DEVELOPMENT INC
NASDAQ: XLO (Xilio Therapeutics, Inc.)
Kemas kini terakhir: 19 minit lalu8.93
-0.06 (-0.72%)
| Penutupan Terdahulu | 9.00 |
| Jumlah Dagangan | 4,841 |
| Harga / Jualan (P/S) | 2.00 |
| Harga / Buku (P/B) | 0.820 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -472.73% |
| EPS Cair (TTM) | -0.650 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 73.50% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 21.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 19.13 M |
| Pulangan Atas Aset (ROA TTM) | -38.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -297.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Xilio Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.07 |
|
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 45.76% |
| % Dimiliki oleh Institusi | 22.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2026 | 664,021 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 650,389 |
| Orbimed Advisors Llc | 30 Jun 2026 | 592,300 |
| Frazier Life Sciences Management, L.P. | 30 Jun 2026 | 422,505 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 225,994 |
| Vanguard Capital Management Llc | 30 Jun 2026 | 178,517 |
| Sio Capital Management, Llc | 30 Jun 2026 | 152,464 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 111,541 |
| Merck & Co., Inc. | 30 Jun 2026 | 105,982 |
| Vanguard Group Inc | 31 Dec 2025 | 89,694 |
| Renaissance Technologies Llc | 30 Jun 2026 | 64,153 |
| Morgan Stanley | 30 Jun 2026 | 56,954 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2026 | 47,695 |
| Geode Capital Management, Llc | 30 Jun 2026 | 39,055 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |